EN DE
Watch Lucid Diagnostics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lucid Diagnostics Inc (LUCD) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Lucid Diagnostics Inc stock $0.29, price $0.40, that is 27.0% below the price, quality 25 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LD Lucid Diagnostics Inc logo Thin data Nov 10, 2026

Lucid Diagnostics Inc

LUCD · US
Expensive, weak quality

Our calculation puts a fair price 27% below what the stock costs today.

Revenue last quarter +27% vs. a year ago.
Mixed Growth (revenue 3y +132.0 %/yr in USD)
Insiders bought $245,000 (6M)
Fair value $0.2921 · Overvalued
Quality 25/100
Negative free cash flow
Trails peers (1/6)
Narrow moat 12/100
Thin data
Estimate
Watch Lucid Diagnostics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$11.76 $0.3277 Fair Value $0.2921 Oct 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.3277 – $11.76 · fair‑value band $0.2191 – $0.3651 · the $0.4000 price screens above the $0.2921 fair value. As of Nov 10, 2026.

Follow Lucid Diagnostics in your weekly email

Every Wednesday you see whether Lucid Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

Show moreShow less

The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.

The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Stock analysis

Lucid Diagnostics Inc (LUCD) currently trades at $0.4000, while our estimate is $0.2921, 27% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.2191 (bear) to $0.3651 (bull), the price of $0.4000 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lucid Diagnostics Inc reported revenue of $4.7M in FY2025 versus $500K in FY2021, a compound +75.2%/yr. Reported net income was −$58.0M in FY2025.

Key figures

Market cap $73.2M Micro · P/S ratio 14.2 · EPS (TTM) $−0.4400 · Return on equity −556% · Return on assets (EBIT) −134% (5-year average) · Operating margin −868% · Revenue (TTM) $5.4M · Revenue growth (YoY) +26.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 73% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −27%, LUCD screens richer than that median.

Fair Value

Bear $0.2191 Fair Value $0.2921 Bull $0.3651
Price $0.4000 · Downside -27.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 56
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 83
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $245,000, on May 20, 2026.

  • BuyDennis MatheisDirector245,000 shares at $1.00$245,000May 20, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 33/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+132.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,483.8% (2021) → −1,054.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LUCD screens overvalued: fair value 27% below the price. Compare with Abbott Laboratories, →

Compare Lucid Diagnostics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −27.0% · Below median
Profitability
Return on assets −143.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 26.7% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 6.70× · Priciest 25%
P/S (12 months) 13.45× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs LUCD
DexCom, Inc DXCM $79.92 $89.18 +12% vs LUCD
Stryker Corporation SYK $324.29 $358.30 +10% vs LUCD
STERIS plc STE $257.12 $279.53 +9% vs LUCD
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs LUCD
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs LUCD
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs LUCD
Abbott Laboratories, ABT $110.46 $75.28 −32% vs LUCD
Medtronic plc MDT $101.59 $65.61 −35% vs LUCD
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs LUCD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lucid Diagnostics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lucid Diagnostics Inc Fair Value". https://www.fairvalue-calculator.com/stock/LUCD

Frequently asked questions

Is Lucid Diagnostics Inc (LUCD) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.2921 versus a price of $0.4000, about 27% lower (overvalued).
What is the fair value of LUCD?
Our estimate for Lucid Diagnostics Inc is $0.2921 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.4000.
What is the quality score of LUCD?
Lucid Diagnostics Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lucid Diagnostics Inc (LUCD)?
Our calculated price target is the estimate of $0.2921 (as of Nov 10, 2026). Cautious scenario $0.2191, optimistic scenario $0.3651. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Lucid Diagnostics Inc stock forecast for 2026?
Our estimate puts fair value at $0.2921, about 27% lower versus a price of $0.4000 (overvalued). Cautious scenario $0.2191, optimistic scenario $0.3651. The calculation is refreshed regularly with new filings.
What is the revenue of Lucid Diagnostics Inc (LUCD)?
Lucid Diagnostics Inc reported trailing-twelve-month revenue of about $5.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Lucid Diagnostics Inc (LUCD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lucid Diagnostics Inc it is $0.2921 per share (as of Nov 10, 2026), against a price of $0.4000.
Is Lucid Diagnostics Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, LUCD trades above its calculated fair value: price $0.4000, fair value $0.2921, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LUCD?
No. The price is what the market pays today ($0.4000); the fair value is what the company's own numbers justify ($0.2921). For Lucid Diagnostics Inc the two are $0.1079 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lucid Diagnostics Inc worth?
The market values Lucid Diagnostics Inc at about $73.2M (market capitalisation, as of Nov 10, 2026). Per share that is $0.4000; our models calculate a fair value of $0.2921 per share.
What do the bullish and bearish scenarios say about LUCD?
Our models span a range for Lucid Diagnostics Inc: cautious scenario $0.2191, base $0.2921, optimistic $0.3651 per share (as of Nov 10, 2026, price $0.4000). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is LUCD from its 52-week high?
Lucid Diagnostics Inc trades at $0.4000, about 73% below its 52-week high of $1.47 and 22% above the low of $0.3277 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2921 is for.
Which stocks are comparable to Lucid Diagnostics Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lucid Diagnostics Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.4000, calculated fair value $0.2921 (−27%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Lucid Diagnostics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lucid Diagnostics Inc (LUCD)?
The closing price on Nov 10, 2026 was $0.4000. Our estimate is $0.2921, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lucid Diagnostics Inc right now?
The price sits above even our optimistic bull case ($0.3651). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Lucid Diagnostics Inc

How large is the market capitalisation of Lucid Diagnostics Inc (LUCD)?
The market capitalisation of Lucid Diagnostics Inc is $73.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lucid Diagnostics Inc (LUCD)?
The price-to-sales ratio of Lucid Diagnostics Inc is 14.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lucid Diagnostics Inc (LUCD)?
Earnings per share at Lucid Diagnostics Inc are $−0.4400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lucid Diagnostics Inc (LUCD)?
The return on equity (ROE) of Lucid Diagnostics Inc is −556% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lucid Diagnostics Inc (LUCD)?
On an EBIT basis the return on assets of Lucid Diagnostics Inc is −134% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lucid Diagnostics Inc (LUCD)?
The operating margin of Lucid Diagnostics Inc is −868% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lucid Diagnostics Inc (LUCD)?
Revenue at Lucid Diagnostics Inc is growing +26.7% versus a year earlier (3y avg +132%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lucid Diagnostics Inc (LUCD) generate?
The free cash flow of Lucid Diagnostics Inc is −$46.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lucid Diagnostics Inc (LUCD) hold?
Lucid Diagnostics Inc holds more cash than debt, $8.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lucid Diagnostics Inc in the live analysis

One click puts Lucid Diagnostics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.